Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC lowered its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 18.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,748 shares of the company’s stock after selling 2,696 shares during the quarter. ProShare Advisors LLC’s holdings in Twist Bioscience were worth $579,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after buying an additional 44,349 shares during the last quarter. UBS Group AG increased its position in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock worth $7,868,000 after purchasing an additional 110,036 shares in the last quarter. SageView Advisory Group LLC acquired a new position in Twist Bioscience in the 1st quarter valued at $1,144,000. Susquehanna Fundamental Investments LLC purchased a new position in Twist Bioscience in the 1st quarter valued at $300,000. Finally, Sei Investments Co. lifted its holdings in Twist Bioscience by 32.7% in the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after purchasing an additional 55,124 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 709 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares in the company, valued at $3,154,310.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Twist Bioscience news, CFO Adam Laponis sold 842 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the transaction, the chief financial officer now owns 73,602 shares in the company, valued at approximately $3,599,873.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dennis Cho sold 709 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,386 shares of company stock worth $770,915. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $46.39 on Monday. The business has a 50-day moving average of $46.31 and a two-hundred day moving average of $43.42. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of -13.81 and a beta of 1.76. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. During the same quarter last year, the firm posted ($1.01) EPS. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. As a group, equities research analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TWST. The Goldman Sachs Group raised their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Robert W. Baird raised their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $50.88.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.